Response by Eli Lilly: re allegations of opposing patent reforms on access to medicines in So. Africa

Data:: 19 Mar 2014
Content Type:: Company Response

Available languages: English

Servier did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Data:: 10 Mar 2014
Content Type:: Company Response

Available languages: English

Ferring Pharmaceuticals did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Data:: 10 Mar 2014
Content Type:: Company Response

Available languages: English

Amgen did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Data:: 10 Mar 2014
Content Type:: Company Response

Available languages: English

AbbVie did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Data:: 10 Mar 2014
Content Type:: Company Response

Available languages: English

Response by Norgine Pharmaceuticals: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Data:: 10 Mar 2014
Content Type:: Company Response

Available languages: English

Abbott Laboratories did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Data:: 10 Mar 2014
Content Type:: Company Response

Available languages: English

Sanofi did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine

Data:: 9 Mar 2014
Content Type:: Company Response

Available languages: English

Response by Covidien: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 23 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Johnson & Johnson: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Novartis: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Takeda Pharmaceutical: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Pfizer: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Novo Nordisk (part of Novo Group): Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Boehringer Ingelheim: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Merck: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Galderma: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by AstraZeneca: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Baxter International: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by GE Health (part of General Electric): Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 19 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Bayer: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 18 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Allergan: re allegations of opposing patent reforms on access to medicines in So. Africa

Data:: 17 Feb 2014
Content Type:: Company Response

Available languages: English

Response by Bristol-Myers Squibb: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Data:: 17 Feb 2014
Content Type:: Company Response

Available languages: English

Business & Human Rights
Resource Centre

Business & Human Rights Resource Centre

This page is not available in Italiano and is being displayed in English

Response by Eli Lilly: re allegations of opposing patent reforms on access to medicines in So. Africa

Sequenza temporale